Documents / Official release
This Defense Intelligence Reference Document, dated 7 January 2010, was prepared by the Defense Intelligence Agency's Defense Warning Office. It is one of a series of advanced technology reports produced in FY 2009 under the Advanced Aerospace Weapon System Applications program. The report reviews biomaterials used in medicine, including silicones, Teflon, biodegradable polymers, hydrogels, titanium, ceramics and tissue constructs, and applications such as stents, joints, contact lenses, drug delivery and dialysis. It concludes that most innovation lies in new ways to apply existing materials.
From the source:Release of 2026-09-18 Incident: 1/7/10, Las Vegas, Nevada. Released with redactions. This document is a Defense Intelligence Reference Document (DIRD), a technical reference format used by the Defense Intelligence Agency (DIA) to capture baseline knowledge on a specific topic for later analytic use. DIRDs are best understood as reference and synthesis products rather than as original research. It is one of 38 DIRDs produced under the Advanced Aerospace Weapon System Applications Program (AAWSAP) between 2009 and 2011. Because AAWSAP’s scope permitted a broad range of supporting topics, not every DIRD in the series directly concerns aerospace systems or future threat assessment. The following summary reflects the DIRD’s scope and framing at the time of writing and should not be read as implying current validation of the concepts discussed. This DIRD is a broad survey of biomaterials, including metals, polymers, ceramics, glasses, and composites designed to interact with living tissue, and argues that their value depends mainly on biocompatibility, reliability, and careful matching of material properties to specific medical uses. The report reviews major application areas including biosensors, implants, cardiovascular devices, contact lenses, drug delivery systems, tissue constructs, titanium devices, and dialysis membranes, emphasizing that no single biomaterial works best in every setting. Its overall conclusion is that biomaterials are already foundational to a large medical-device industry and save or improve millions of lives, but that progress tends to be slow because safety testing is stringent; as a result, most advances come from improved ways of applying established materials such as silicone, Teflon, biodegradable polymers, ceramics, and titanium in new devices and clinical settings rather than from radically new substances.
UNCLASSIFIED/ JPOI\ OPPICIJ!tt l:l!H! 8,.LY A problem most materials cause when in blood contact is that they trigger the rapid formation of thrombus (an aggregation of blood cells) . The formation of a thrombus is dangerous, as the thrombus could either adhere to the surface of the biomaterial or be detached. If a thrombus is detached, it can travel in the blood stream and occlude smaller vessels in the brain (called a stroke) or lungs (called an embolism). Some small-diameter vascular grafts ( < 5-millimeter internal diameter) and prostheses for reconstruction of diseased veins are "safe" only when anticoagulant drugs are used. In addition to thrombus formation, biomaterials can become colonized with infection causing bacteria. Some microorganisms found in hospitals are extremely resistant to antibiotic therapy, and infections cannot be fully resolved until the biomaterial is removed. This is particularly a problem with hip and knee implants, where there is poor blood flow near the joint and the body's immune system has limited access. Methicillin resistant staphylococcus aureus infections are dangerous in these situations. The high tolerance of the body for woven and formed Teflon allows it to be used as a flexible patch material for other blood-contacting surfaces, in addition to blood vessels. For example, Gore, Inc., makes a Teflon-based material that is used to patch holes in the heart of infants born with atrial septal defects. Figure 23 is an artist's conception of how the patch is inserted into the hole in the atrial wall using a catheter. Figure 23. Illustration of Treatment of an Atrial Septal Defect Using a Teflon-Based Product Manufactured by Gore, Inc. UNCLASSIFIED/ ;<fOA OFFICI.I ~ 1Pili Qtl! X 17
Not linked to a story yet.
Official release, from the pursue collection. The PDF is mirrored here; the original link is above. 32 pages are in the text index: search them above, or from the library's search.